Lobeglitazone
Cross-source consensus on Lobeglitazone from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Comparisons
Where it comes from
Highlighted claims
- The study evaluated whether lobeglitazone was linked to lower renal disease progression in adults with type 2 diabetes using Korean hospital data. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
- Lobeglitazone plus metformin was not associated with a statistically significant change in renal progression compared with the studied comparator regimens. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
- Lobeglitazone is a thiazolidinedione used in Korea for type 2 diabetes treatment. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
- Lobeglitazone plus metformin produced renal outcomes comparable to metformin monotherapy, sulfonylurea plus metformin, and DPP4 inhibitor plus metformin. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
- Lobeglitazone has high affinity for PPAR-gamma because it incorporates a pyrimidine substituent into the thiazolidinedione scaffold. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study